<?xml version="1.0" encoding="UTF-8"?>
<?xml-stylesheet href="/rss.css" type="text/css"?>
<rdf:RDF xmlns="http://purl.org/rss/1.0/"
    xmlns:cc="http://web.resource.org/cc/"
    xmlns:dc="http://purl.org/dc/elements/1.1/"
    xmlns:extra="http://www.w3.org/1999/xhtml"
    xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/"
    xmlns:rdf="http://www.w3.org/1999/02/22-rdf-syntax-ns#">
    <channel rdf:about="http://www.retrovirology.com/feeds/latestarticles/journal?quantity=&amp;format=rss&amp;version=">
        <title>Retrovirology - Latest Articles</title>
        <link>http://www.retrovirology.com</link>
        <description>The latest research articles published by Retrovirology</description>
        <dc:date>2012-05-14T00:00:00Z</dc:date>
        <items>
            <rdf:Seq>
                                <rdf:li rdf:resource="http://www.retrovirology.com/content/9/1/42" />
                                <rdf:li rdf:resource="http://www.retrovirology.com/content/9/1/41" />
                                <rdf:li rdf:resource="http://www.retrovirology.com/content/9/1/40" />
                                <rdf:li rdf:resource="http://www.retrovirology.com/content/9/1/39" />
                                <rdf:li rdf:resource="http://www.retrovirology.com/content/9/1/38" />
                                <rdf:li rdf:resource="http://www.retrovirology.com/content/9/1/37" />
                                <rdf:li rdf:resource="http://www.retrovirology.com/content/9/1/36" />
                                <rdf:li rdf:resource="http://www.retrovirology.com/content/9/1/35" />
                                <rdf:li rdf:resource="http://www.retrovirology.com/content/9/1/34" />
                                <rdf:li rdf:resource="http://www.retrovirology.com/content/9/1/33" />
                            </rdf:Seq>
        </items>
                 <cc:license rdf:resource="http://creativecommons.org/licenses/by/2.0/" />
    </channel>
        <item rdf:about="http://www.retrovirology.com/content/9/1/42">
        <title>T cell independent secondary antibody responses to the envelope protein of simian immunodeficiency virus</title>
        <description>Background:
During human (HIV) and simian (SIV) immunodeficiency virus infection, loss of CD4+ T cells and progression to AIDS are associated with a decline in antibody titers to the viral Gag protein, while antibodies to the Env protein remain high, suggesting a T cell independent antibody response to Env.
Results:
To explore differential regulation of Gag and Env antibody responses, immunocompetent BALB/c and T cell deficient nude mice were immunized with virus like particles (VLP) of simian immunodeficiency virus or adenoviral vectors expressing SIV Gag and Env. High levels of antibodies against Gag and Env could only be induced in immunocompetent mice, but not in the immunodeficient mice. Thus, neither cells expressing Env after adenoviral gene transfer nor VLPs induce a T cell independent primary anti-Env antibody response. However, secondary B cell responses to Env, but not to Gag, were observed in immunodeficient mice after transfer of primed B cells and boosting with VLPs or adenoviral vectors expressing Gag and Env. This T cell independent secondary antibody response to Env was reduced after stimulation with VLPs modified to contain monomeric membrane bound gp130 surface subunit of Env and undetectable after injection of soluble gp130.
Conclusions:
Membrane-bound trimeric Env seems to be responsible for the maintenance of high levels of anti-Env antibodies during progression to AIDS. This T cell independent secondary antibody response may prevent T cell-dependent affinity maturation and thus contribute to viral immune escape by favoring persistence of non-protective antibodies.</description>
        <link>http://www.retrovirology.com/content/9/1/42</link>
                <dc:creator>Ghulam Nabi</dc:creator>
                <dc:creator>Vladimir Temchura</dc:creator>
                <dc:creator>Claudius Großmann</dc:creator>
                <dc:creator>Seraphin Kuate</dc:creator>
                <dc:creator>Matthias Tenbusch</dc:creator>
                <dc:creator>Klaus Überla</dc:creator>
                <dc:source>Retrovirology 2012, null:42</dc:source>
        <dc:date>2012-05-14T00:00:00Z</dc:date>
        <dc:identifier>doi:10.1186/1742-4690-9-42</dc:identifier>
                                    <dc:description>Membrane-bound trimeric Env seems to be responsible for the maintenance of high levels of anti-Env antibodies during progression to AIDS. This T cell independent secondary antibody response may prevent T cell-dependent affinity maturation and thus contribute to viral immune escape by favoring persistence of non-protective antibodies.</dc:description>
                <prism:require>/content/figures/1742-4690-9-42-toc.gif</prism:require>
                <prism:publicationName>Retrovirology</prism:publicationName>
        <prism:issn>1742-4690</prism:issn>
        <prism:volume>${item.volume}</prism:volume>
        <prism:startingPage>42</prism:startingPage>
        <prism:publicationDate>2012-05-14T00:00:00Z</prism:publicationDate>
                <prism:versionidentifier>PDF</prism:versionidentifier>
                <cc:license rdf:resource="http://creativecommons.org/licenses/by/2.0/" />
    </item>
        <item rdf:about="http://www.retrovirology.com/content/9/1/41">
        <title>The prototype foamy virus protease is active independently of the integrase domain </title>
        <description>Background:
Recently, contradictory results on foamy virus protease activity were published. While our own results indicated that protease activity is regulated by the viral RNA, others suggested that the integrase is involved in the regulation of the protease.
Results:
To solve this discrepancy we performed additional experiments showing that the protease-reverse transcriptase (PR-RT) exhibits protease activity in vitro and in vivo, which is independent of the integrase domain. In contrast, Pol incorporation, and therefore PR activity in the viral context, is dependent on the integrase domain. To further analyse the regulation of the protease, we incorporated Pol in viruses by expressing a GagPol fusion protein, which supported near wild-type like infectivity. A GagPR-RT fusion, lacking the integrase domain, also resulted in wild-type like Gag processing, indicating that the integrase is dispensable for viral Gag maturation. Furthermore, we demonstrate with a trans-complementation assays that the PR in the context of the PR-RT protein supports in trans both, viral maturation and infectivity.
Conclusion:
We provide evidence that the FV integrase is required for Pol encapsidation and that the FV PR activity is integrase independent. We show that an active PR can be encapsidated in trans as a GagPR-RT fusion protein.</description>
        <link>http://www.retrovirology.com/content/9/1/41</link>
                <dc:creator>Ralf Spannaus</dc:creator>
                <dc:creator>Maximilian Hartl</dc:creator>
                <dc:creator>Birgitta Wöhrl</dc:creator>
                <dc:creator>Axel Rethwilm</dc:creator>
                <dc:creator>Jochen Bodem</dc:creator>
                <dc:source>Retrovirology 2012, null:41</dc:source>
        <dc:date>2012-05-10T00:00:00Z</dc:date>
        <dc:identifier>doi:10.1186/1742-4690-9-41</dc:identifier>
                                    <dc:description>This paper shows that the FV integrase is required for Pol encapsidation and that the FV PR activity is integrase independent. The study shows that an active PR can be encapsidated in trans as a GagPR-RT fusion protein.</dc:description>
                <prism:require>/content/figures/1742-4690-9-41-toc.gif</prism:require>
                <prism:publicationName>Retrovirology</prism:publicationName>
        <prism:issn>1742-4690</prism:issn>
        <prism:volume>${item.volume}</prism:volume>
        <prism:startingPage>41</prism:startingPage>
        <prism:publicationDate>2012-05-10T00:00:00Z</prism:publicationDate>
                <prism:versionidentifier>PDF</prism:versionidentifier>
                <cc:license rdf:resource="http://creativecommons.org/licenses/by/2.0/" />
    </item>
        <item rdf:about="http://www.retrovirology.com/content/9/1/40">
        <title>Limited SHIV env diversification in macaques failing oral antiretroviral pre-exposure prophylaxis</title>
        <description>Background:
Pre-exposure prophylaxis (PrEP) with daily Truvada [a combination of emtricitabine (FTC) and tenofovir disoproxil fumarate (TDF)] is a novel HIV prevention strategy recently found to prevent HIV transmission among men who have sex with men and heterosexual couples. Acute infection in persons who fail PrEP will inevitably occur under concurrent antiretroviral therapy, thus raising questions regarding the potential impact of PrEP on early viral dynamics. We investigated viral evolution dynamics in a macaque model of PrEP consisting of repeated rectal exposures to SHIV162P3 in the presence of PrEP.
Results:
Two macaques were infected during daily or intermittent PrEP with FTC or FTC/TDF, and five were untreated controls. SHIV env sequence evolution was monitored by single genome amplification with phylogenetic and sequence analysis. Mean nucleotide divergence from transmitted founder viruses calculated 17 weeks (range = 12-20) post peak viremia was significantly lower in PrEP failures than in control animals (7.2 &#215; 10-3 compared to 1.6 &#215; 10-2 nucleotide substitutions per site per year, respectively, p &lt; 0.0001). Mean virus diversity was also lower in PrEP failures after 17 weeks (0.13% vs. 0.53% in controls, p &lt; 0.0001).
Conclusions:
Our results in a macaque model of acute HIV infection suggest that infection during PrEP limits early virus evolution likely because of a direct antiviral effect of PrEP and/or reduced target cell availability. Reduced virus diversification during early infection might enhance immune control by slowing the selection of escape mutants.</description>
        <link>http://www.retrovirology.com/content/9/1/40</link>
                <dc:creator>Qi Zheng</dc:creator>
                <dc:creator>Susan Ruone</dc:creator>
                <dc:creator>William Switzer</dc:creator>
                <dc:creator>Walid Heneine</dc:creator>
                <dc:creator>J Gerardo García-Lerma</dc:creator>
                <dc:source>Retrovirology 2012, null:40</dc:source>
        <dc:date>2012-05-09T00:00:00Z</dc:date>
        <dc:identifier>doi:10.1186/1742-4690-9-40</dc:identifier>
                                    <dc:description>Infection during pre-exposure prophylaxis (PrEP) limits early virus evolution likely because of a direct antiviral effect of PrEP and/or reduced target cell availability. Reduced virus diversification during early infection might enhance immune control by slowing the selection of escape mutants</dc:description>
                <prism:require>/content/figures/1742-4690-9-40-toc.gif</prism:require>
                <prism:publicationName>Retrovirology</prism:publicationName>
        <prism:issn>1742-4690</prism:issn>
        <prism:volume>${item.volume}</prism:volume>
        <prism:startingPage>40</prism:startingPage>
        <prism:publicationDate>2012-05-09T00:00:00Z</prism:publicationDate>
                <prism:versionidentifier>PDF</prism:versionidentifier>
                <cc:license rdf:resource="http://creativecommons.org/licenses/by/2.0/" />
    </item>
        <item rdf:about="http://www.retrovirology.com/content/9/1/39">
        <title>HLA-C and HIV-1: Friends or Foes?</title>
        <description>The major histocompatibility complex class I protein HLA-C plays a crucial role as a molecule capable of sending inhibitory signals to both natural killer (NK) cells and cytotoxic T lymphocytes (CTL) via binding to killer cell Ig-like receptors (KIR). Recently HLA-C has been recognized as a key molecule in the immune control of HIV-1. Expression of HLA-C is modulated by a microRNA binding site. HLA-C alleles that bear substitutions in the microRNA binding site are more expressed at the cell surface and associated with the control of HIV-1 viral load, suggesting a role of HLA-C in the presentation of antigenic peptides to CTLs. This review highlights the role of HLA-C in association with HIV-1 viral load, but also addresses the contradiction of the association between high cell surface expression of an inhibitory molecule and strong cell-mediated immunity. To explore additional mechanisms of control of HIV-1 replication by HLA-C, we address specific features of the molecule, like its tendency to be expressed as open conformer upon cell activation, which endows it with a unique capacity to associate with other cell surface molecules as well as with HIV-1 proteins.</description>
        <link>http://www.retrovirology.com/content/9/1/39</link>
                <dc:creator>Donato Zipeto</dc:creator>
                <dc:creator>Alberto Beretta</dc:creator>
                <dc:source>Retrovirology 2012, null:39</dc:source>
        <dc:date>2012-05-09T00:00:00Z</dc:date>
        <dc:identifier>doi:10.1186/1742-4690-9-39</dc:identifier>
                                    <dc:description>This review highlights the role of HLA-C in association with HIV-1 viral load, but also addresses the contradiction of the association between high cell surface expression of an inhibitory molecule and strong cell-mediated immunity. To explore additional mechanisms of control of HIV-1 replication by HLA-C, this review addresses specific features of the molecule, like its tendency to be expressed as open conformer upon cell activation, which endows it with a unique capacity to associate with other cell surface molecules as well as with HIV-1 proteins.</dc:description>
                <prism:require>/content/figures/1742-4690-9-39-toc.gif</prism:require>
                <prism:publicationName>Retrovirology</prism:publicationName>
        <prism:issn>1742-4690</prism:issn>
        <prism:volume>${item.volume}</prism:volume>
        <prism:startingPage>39</prism:startingPage>
        <prism:publicationDate>2012-05-09T00:00:00Z</prism:publicationDate>
                <prism:versionidentifier>PDF</prism:versionidentifier>
                <cc:license rdf:resource="http://creativecommons.org/licenses/by/2.0/" />
    </item>
        <item rdf:about="http://www.retrovirology.com/content/9/1/38">
        <title>HIV-1-encoded antisense RNA suppresses viral replication for a prolonged period</title>
        <description>Background:
Recent evidence proposes a novel concept that mammalian natural antisense RNAs play important roles in cellular homeostasis by regulating the expression of several genes. Identification and characterization of retroviral antisense RNA would provide new insights into mechanisms of replication and pathogenicity. HIV-1 encoded-antisense RNAs have been reported, whereas the accurate structures and functions remain to be studied. Thus, we tried to identify and characterize antisense RNAs of HIV-1 and studied their function in viral infection.
Results:
Characterization of transcripts of HEK293T cells that were transiently transfected with an expression plasmid with HIV-1NL4-3 DNA in the antisense orientation showed that various antisense transcripts can be expressed. By screening and characterization of antisense RNAs in HIV-1NL4-3-infected cells, we defined the primary structure of a major form of HIV-1 antisense RNAs, which corresponds to a variant of previously reported ASP mRNA. This 2.6kb RNA was transcribed from the U3 region of the 3&apos;  LTR and terminated at the env region in acutely or chronically infected cell lines and acutely infected human peripheral blood mononuclear cells. Reporter assays clearly demonstrated that the HIV-1 LTR harbours promoter activity in the reverse orientation. Mutation analyses suggested involvement of NF- binding sites in the regulation of antisense transcription. The antisense RNA was localized in the nuclei of the infected cells. Expression of the antisense RNA suppressed HIV-1 replication for more than one month. Furthermore, specific knockdown of the antisense RNA resulted in an enhancement of HIV-1 gene expression and replication.
Conclusions:
The results of the present study identified an accurate structure of the major form of antisense RNAs expressed from the HIV-1NL4-3 provirus and demonstrated its nuclear localization. Functional studies collectively demonstrated a new role of the antisense RNA in the viral replication, thus we suggest a novel viral mechanism that regulates self-limiting replication of HIV-1, providing a new insight into viral life cycles.</description>
        <link>http://www.retrovirology.com/content/9/1/38</link>
                <dc:creator>Mie Kobayashi-Ishihara</dc:creator>
                <dc:creator>Makoto Yamagishi</dc:creator>
                <dc:creator>Takuma Hara</dc:creator>
                <dc:creator>Yuka Matsuda</dc:creator>
                <dc:creator>Ryutaro Takahashi</dc:creator>
                <dc:creator>Ariko Miyake</dc:creator>
                <dc:creator>Kazumi Nakano</dc:creator>
                <dc:creator>Tadanori Yamochi</dc:creator>
                <dc:creator>Takaomi Ishida</dc:creator>
                <dc:creator>Toshiki Watanabe</dc:creator>
                <dc:source>Retrovirology 2012, null:38</dc:source>
        <dc:date>2012-05-08T00:00:00Z</dc:date>
        <dc:identifier>doi:10.1186/1742-4690-9-38</dc:identifier>
                                    <dc:description>The present study identified an accurate structure of the major form of antisense RNAs expressed from the HIV-1NL4-3 provirus and demonstrated a new role of the antisense RNA in viral replication, suggesting a novel viral mechanism that regulates self-limited replication of HIV-1.</dc:description>
                <prism:require>/content/figures/1742-4690-9-38-toc.gif</prism:require>
                <prism:publicationName>Retrovirology</prism:publicationName>
        <prism:issn>1742-4690</prism:issn>
        <prism:volume>${item.volume}</prism:volume>
        <prism:startingPage>38</prism:startingPage>
        <prism:publicationDate>2012-05-08T00:00:00Z</prism:publicationDate>
                <prism:versionidentifier>PDF</prism:versionidentifier>
                <cc:license rdf:resource="http://creativecommons.org/licenses/by/2.0/" />
    </item>
        <item rdf:about="http://www.retrovirology.com/content/9/1/37">
        <title>Protein kinase C-delta regulates HIV-1 replication at an early post-entry step in macrophages</title>
        <description>Background:
Macrophages, which are CD4 and CCR5 positive, can sustain HIV-1 replication for long periods of time. Thus, these cells play critical roles in the transmission, dissemination and persistence of viral infection. Of note, current antiviral therapies do not target macrophages efficiently. Previously, it was demonstrated that interactions between CCR5 and gp120 stimulate PKC. However, the PKC isozymes involved were not identified.
Results:
In this study, we identified PKC-delta as a major cellular cofactor for HIV-1 replication in macrophages. Indeed, PKC-delta was stimulated following the interaction between the virus and its target cell. Moreover, inhibition of PKC-delta blocked the replication of R5-tropic viruses in primary human macrophages. However, this inhibition did not have significant effects on receptor and co-receptor expression or fusion. Additionally, it did not affect the formation of the early reverse transcription product containing R/U5 sequences, but did inhibit the synthesis of subsequent cDNAs. Importantly, the inhibition of PKC-delta altered the redistribution of actin, a cellular cofactor whose requirement for the completion of reverse transcription was previously established. It also prevented the association of the reverse transcription complex with the cytoskeleton.
Conclusion:
This work highlights the importance of PKC-delta during early steps of the replicative cycle of HIV-1 in human macrophages.</description>
        <link>http://www.retrovirology.com/content/9/1/37</link>
                <dc:creator>Xavier Contreras</dc:creator>
                <dc:creator>Olfa Mzoughi</dc:creator>
                <dc:creator>Fabrice Gaston</dc:creator>
                <dc:creator>B Matija Peterlin</dc:creator>
                <dc:creator>Elmostafa Bahraoui</dc:creator>
                <dc:source>Retrovirology 2012, null:37</dc:source>
        <dc:date>2012-05-03T00:00:00Z</dc:date>
        <dc:identifier>doi:10.1186/1742-4690-9-37</dc:identifier>
                                    <dc:description>This study identified PKC-delta as a major cellular cofactor for HIV-1 replication in macrophages. PKC-delta was stimulated following the interaction between the virus and its target cell. Inhibition of PKC-delta blocked the replication of R5-tropic viruses in primary human macrophages.</dc:description>
                <prism:require>/content/figures/1742-4690-9-37-toc.gif</prism:require>
                <prism:publicationName>Retrovirology</prism:publicationName>
        <prism:issn>1742-4690</prism:issn>
        <prism:volume>${item.volume}</prism:volume>
        <prism:startingPage>37</prism:startingPage>
        <prism:publicationDate>2012-05-03T00:00:00Z</prism:publicationDate>
                <prism:versionidentifier>PDF</prism:versionidentifier>
                <cc:license rdf:resource="http://creativecommons.org/licenses/by/2.0/" />
    </item>
        <item rdf:about="http://www.retrovirology.com/content/9/1/36">
        <title>MiniCD4 protein resistance mutations affect binding to the HIV-1 gp120 CD4 binding site and decrease entry efficiency</title>
        <description>Background:
Binding of the viral envelope protein (Env), and particularly of its gp120 subunit, to the cellular CD4 receptor is the first essential step of the HIV-1 entry process. The CD4 binding site (CD4bs) of gp120, and especially a recessed cavity occupied by the CD4 Phe43 residue, are known to be highly conserved among the different circulating subtypes and therefore constitute particularly interesting targets for vaccine and drug design. The miniCD4 proteins are a promising class of CD4bs inhibitors. Studying virus evolution under pressure of CD4bs inhibitors could provide insight on the gp120-CD4 interaction and viral entry.
Results:
The present study reports on the resistance induction of two subtype B HIV-1 against the most active miniCD4, M48U1, and its ancestor, M48, and how these mutated positions affect CD4bs recognition, entry efficiency, and sensitivity to other CD4bs inhibitors. Resistance against M48U1 was always associated with S375R/N substitution in both BaL and SF162; M48 resistance was associated with D474N substitution in SF162 and with H105Y substitution in BaL. In addition, some other mutations at position V255 and G471 were of importance for SF162 resistant viruses. Except for 474, all of these mutated positions are conserved, and introducing them into an SF162 Env expressing infectious molecular clone (pBRNL4.3 SF162) resulted in decreased entry efficiency. Furthermore, resistant mutants showed at least some cross-resistance towards other CD4bs inhibitors, the V3 monoclonal antibody 447-52D and some even against the monoclonal antibody 17b, of which the epitope overlaps the co-receptor binding site.
Conclusions:
The mutations H105Y, V255M, S375R/N, G471R/E, and D474N are found to be involved in resistance towards M48 and M48U1. All mutated positions are part of, or in close proximity to, the CD4bs; most are highly conserved, and all have an impact on the entry efficiency, suggesting their importance for optimal virus infectivity.</description>
        <link>http://www.retrovirology.com/content/9/1/36</link>
                <dc:creator>Katrijn Grupping</dc:creator>
                <dc:creator>Philippe Selhorst</dc:creator>
                <dc:creator>Johan Michiels</dc:creator>
                <dc:creator>Katleen Vereecken</dc:creator>
                <dc:creator>Leo Heyndrickx</dc:creator>
                <dc:creator>Pascal Kessler</dc:creator>
                <dc:creator>Guido Vanham</dc:creator>
                <dc:creator>Loïc Martin</dc:creator>
                <dc:creator>Kevin Ariën</dc:creator>
                <dc:source>Retrovirology 2012, null:36</dc:source>
        <dc:date>2012-05-02T00:00:00Z</dc:date>
        <dc:identifier>doi:10.1186/1742-4690-9-36</dc:identifier>
                                    <dc:description>The present study reports on the resistance induction of two subtype B HIV-1 against the most active miniCD4, M48U1, and its ancestor, M48, and how these mutated positions affect CD4bs recognition, entry efficiency, and sensitivity to other CD4bs inhibitors. Resistance against M48U1 was always associated with S375R/N substitution in both BaL and SF162; M48 resistance was associated with D474N substitution in SF162 and with H105Y substitution in BaL.</dc:description>
                <prism:require>/content/figures/1742-4690-9-36-toc.gif</prism:require>
                <prism:publicationName>Retrovirology</prism:publicationName>
        <prism:issn>1742-4690</prism:issn>
        <prism:volume>${item.volume}</prism:volume>
        <prism:startingPage>36</prism:startingPage>
        <prism:publicationDate>2012-05-02T00:00:00Z</prism:publicationDate>
                <prism:versionidentifier>PDF</prism:versionidentifier>
                <cc:license rdf:resource="http://creativecommons.org/licenses/by/2.0/" />
    </item>
        <item rdf:about="http://www.retrovirology.com/content/9/1/35">
        <title>Emerging complexities of APOBEC3G action on immunity and viral fitness during HIV infection and treatment</title>
        <description>The enzyme APOBEC3G (A3G) mutates the human immunodeficiency virus (HIV) genome by converting deoxycytidine (dC) to deoxyuridine (dU) on minus strand viral DNA during reverse transcription. A3G restricts viral propagation by degrading or incapacitating the coding ability of the HIV genome. Thus, this enzyme has been perceived as an innate immune barrier to viral replication whilst adaptive immunity responses escalate to effective levels. The discovery of A3G less than a decade ago led to the promise of new anti-viral therapies based on manipulation of its cellular expression and/or activity. The rationale for therapeutic approaches has been solidified by demonstration of the effectiveness of A3G in diminishing viral replication in cell culture systems of HIV infection, reports of its mutational footprint in virions from patients, and recognition of its unusually robust enzymatic potential in biochemical studies in vitro. Despite its effectiveness in various experimental systems, numerous recent studies have shown that the ability of A3G to combat HIV in the physiological setting is severely limited. In fact, it has become apparent that its mutational activity may actually enhance viral fitness by accelerating HIV evolution towards the evasion of both anti-viral drugs and the immune system. This body of work suggests that the role of A3G in HIV infection is more complex than heretofore appreciated and supports the hypothesis that HIV has evolved to exploit the action of this host factor. Here, we present an overview of recent data that bring to light historical overestimation of A3G&apos;s standing as a strictly anti-viral agent. We discuss the limitations of experimental systems used to assess its activities as well as caveats in data interpretation.</description>
        <link>http://www.retrovirology.com/content/9/1/35</link>
                <dc:creator>Mahdis Monajemi</dc:creator>
                <dc:creator>Claire Woodworth</dc:creator>
                <dc:creator>Jessica Benkaroun</dc:creator>
                <dc:creator>Michael Grant</dc:creator>
                <dc:creator>Mani Larijani</dc:creator>
                <dc:source>Retrovirology 2012, null:35</dc:source>
        <dc:date>2012-04-30T00:00:00Z</dc:date>
        <dc:identifier>doi:10.1186/1742-4690-9-35</dc:identifier>
                                    <dc:description>Despite its effectiveness in various experimental systems, numerous recent studies have shown that the ability of A3G to combat HIV in the physiological setting is severely limited. In fact, it has become apparent that A3G&apos;s mutational activity may actually enhance viral fitness by accelerating HIV evolution towards the evasion of both anti-viral drugs and the immune system.  Here the authors present an overview of recent data that bring to light historical overestimation of A3G&apos;s standing as a strictly anti-viral agent.</dc:description>
                <prism:require>/content/figures/1742-4690-9-35-toc.gif</prism:require>
                <prism:publicationName>Retrovirology</prism:publicationName>
        <prism:issn>1742-4690</prism:issn>
        <prism:volume>${item.volume}</prism:volume>
        <prism:startingPage>35</prism:startingPage>
        <prism:publicationDate>2012-04-30T00:00:00Z</prism:publicationDate>
                <prism:versionidentifier>PDF</prism:versionidentifier>
                <cc:license rdf:resource="http://creativecommons.org/licenses/by/2.0/" />
    </item>
        <item rdf:about="http://www.retrovirology.com/content/9/1/34">
        <title>Identification of a highly conserved valine-glycine-phenylalanine amino acid triplet required for HIV-1 Nef function</title>
        <description>Background:
The Nef protein of HIV facilitates virus replication and disease progression in infected patients. This role as pathogenesis factor depends on several genetically separable Nef functions that are mediated by interactions of highly conserved protein-protein interaction motifs with different host cell proteins. By studying the functionality of a series of nef alleles from clinical isolates, we identified a dysfunctional HIV group O Nef in which a highly conserved valine-glycine-phenylalanine (VGF) region, which links a preceding acidic cluster with the following proline-rich motif into an amphipathic surface was deleted. In this study, we aimed to study the functional importance of this VGF region.
Results:
The dysfunctional HIV group O8 nef allele was restored to consensus sequence, and mutants of canonical (NL4.3, NA-7, SF2) and non-canonical (B2 and C1422) HIV-1 group M nef alleles were generated in which the amino acids of the VGF region were changed into alanines (VGF-&gt;AAA) and tested for their capacity to interfere with surface receptor trafficking, signal transduction and enhancement of viral replication and infectivity. We found the VGF motif, and each individual amino acid of this motif, to be critical for downregulation of MHC-I and CXCR4. Moreover, Nef&apos;s association with the cellular p21-activated kinase 2 (PAK2), the resulting deregulation of cofilin and inhibition of host cell actin remodeling, and targeting of Lck kinase to the trans-golgi-network (TGN) were affected as well. Of particular interest, VGF integrity was essential for Nef-mediated enhancement of HIV virion infectivity and HIV replication in peripheral blood lymphocytes. For targeting of Lck kinase to the TGN and viral infectivity, especially the phenylalanine of the triplet was essential. At the molecular level, the VGF motif was required for the physical interaction of the adjacent proline-rich motif with Hck.
Conclusion:
Based on these findings, we propose that this highly conserved three amino acid VGF motif together with the acidic cluster and the proline-rich motif form a previously unrecognized amphipathic surface on Nef. This surface appears to be essential for the majority of Nef functions and thus represents a prime target for the pharmacological inhibition of Nef.</description>
        <link>http://www.retrovirology.com/content/9/1/34</link>
                <dc:creator>Pieter Meuwissen</dc:creator>
                <dc:creator>Bettina Stolp</dc:creator>
                <dc:creator>Veronica Iannucci</dc:creator>
                <dc:creator>Jolien Vermeire</dc:creator>
                <dc:creator>Evelien Naessens</dc:creator>
                <dc:creator>Kalle Saksela</dc:creator>
                <dc:creator>Matthias Geyer</dc:creator>
                <dc:creator>Guido Vanham</dc:creator>
                <dc:creator>Kevin Arien</dc:creator>
                <dc:creator>Oliver Fackler</dc:creator>
                <dc:creator>Bruno Verhasselt</dc:creator>
                <dc:source>Retrovirology 2012, null:34</dc:source>
        <dc:date>2012-04-27T00:00:00Z</dc:date>
        <dc:identifier>doi:10.1186/1742-4690-9-34</dc:identifier>
                                    <dc:description>This study describes a highly conserved three amino acid VGF motif that together with the acidic cluster and the proline-rich motif form a previously unrecognized amphipathic surface on Nef. This surface appears to be essential for the majority of Nef functions and thus represents a prime target for the pharmacological inhibition of Nef.</dc:description>
                <prism:require>/content/figures/1742-4690-9-34-toc.gif</prism:require>
                <prism:publicationName>Retrovirology</prism:publicationName>
        <prism:issn>1742-4690</prism:issn>
        <prism:volume>${item.volume}</prism:volume>
        <prism:startingPage>34</prism:startingPage>
        <prism:publicationDate>2012-04-27T00:00:00Z</prism:publicationDate>
                <prism:versionidentifier>PDF</prism:versionidentifier>
                <cc:license rdf:resource="http://creativecommons.org/licenses/by/2.0/" />
    </item>
        <item rdf:about="http://www.retrovirology.com/content/9/1/33">
        <title>Proteomic analysis of HIV-1 Nef cellular binding partners reveals a role for exocyst complex proteins in mediating enhancement of intercellular nanotube formation</title>
        <description>Background:
HIV-1 Nef protein contributes to pathogenesis via multiple functions that include enhancement of viral replication and infectivity, alteration of intracellular trafficking, and modulation of cellular signaling pathways. Nef stimulates formation of tunneling nanotubes and virological synapses, and is transferred to bystander cells via these intercellular contacts and secreted microvesicles. Nef associates with and activates Pak2, a kinase that regulates T-cell signaling and actin cytoskeleton dynamics, but how Nef promotes nanotube formation is unknown.
Results:
To identify Nef binding partners involved in Pak2-association dependent Nef functions, we employed tandem mass spectrometry analysis of Nef immunocomplexes from Jurkat cells expressing wild-type Nef or Nef mutants defective for the ability to associate with Pak2 (F85L, F89H, H191F and A72P, A75P in NL4-3). We report that wild-type, but not mutant Nef, was associated with 5 components of the exocyst complex (EXOC1, EXOC2, EXOC3, EXOC4, and EXOC6), an octameric complex that tethers vesicles at the plasma membrane, regulates polarized exocytosis, and recruits membranes and proteins required for nanotube formation. Additionally, Pak2 kinase was associated exclusively with wild-type Nef. Association of EXOC1, EXOC2, EXOC3, and EXOC4 with wild-type, but not mutant Nef, was verified by co-immunoprecipitation assays in Jurkat cells. Furthermore, shRNA-mediated depletion of EXOC2 in Jurkat cells abrogated Nef-mediated enhancement of nanotube formation. Using bioinformatic tools, we visualized protein interaction networks that reveal functional linkages between Nef, the exocyst complex, and the cellular endocytic and exocytic trafficking machinery.
Conclusions:
Exocyst complex proteins are likely a key effector of Nef-mediated enhancement of nanotube formation, and possibly microvesicle secretion. Linkages revealed between Nef and the exocyst complex suggest a new paradigm of exocyst involvement in polarized targeting for intercellular transfer of viral proteins and viruses.</description>
        <link>http://www.retrovirology.com/content/9/1/33</link>
                <dc:creator>Joya Mukerji</dc:creator>
                <dc:creator>Kevin Olivieri</dc:creator>
                <dc:creator>Vikas Misra</dc:creator>
                <dc:creator>Kristin Agopian</dc:creator>
                <dc:creator>Dana Gabuzda</dc:creator>
                <dc:source>Retrovirology 2012, null:33</dc:source>
        <dc:date>2012-04-25T00:00:00Z</dc:date>
        <dc:identifier>doi:10.1186/1742-4690-9-33</dc:identifier>
                                    <dc:description>To identify Nef binding partners involved in Pak2-association dependent Nef functions, the authors employed tandem mass spectrometry analysis of Nef immunocomplexes from Jurkat cells expressing wild-type Nef or Nef mutants defective for the ability to associate with Pak2 (F85L, F89H, H191F and A72P, A74P in NL4-3). They report that wild-type, but not mutant Nef, was associated with 5 components of the exocyst complex (EXOC1, EXOC2, EXOC3, EXOC4, and EXOC6), an octameric complex that tethers vesicles at the plasma membrane, regulates polarized exocytosis, and recruits membranes and proteins required for nanotube formation.</dc:description>
                <prism:require>/content/figures/1742-4690-9-33-toc.gif</prism:require>
                <prism:publicationName>Retrovirology</prism:publicationName>
        <prism:issn>1742-4690</prism:issn>
        <prism:volume>${item.volume}</prism:volume>
        <prism:startingPage>33</prism:startingPage>
        <prism:publicationDate>2012-04-25T00:00:00Z</prism:publicationDate>
                <prism:versionidentifier>PDF</prism:versionidentifier>
                <cc:license rdf:resource="http://creativecommons.org/licenses/by/2.0/" />
    </item>
        <cc:License rdf:about="http://creativecommons.org/licenses/by/2.0/">
        <cc:permits rdf:resource="http://creativecommons.org/ns#Reproduction" />
        <cc:permits rdf:resource="http://creativecommons.org/ns#Distribution" />
        <cc:permits rdf:resource="http://creativecommons.org/ns#DerivativeWorks" />
    </cc:License>
</rdf:RDF>

